SARS-CoV-2-IN-112 (Compound 6f) is an orally active, non-peptidic inhibitor of the SARS-CoV-2 main protease with an IC50 of 6.48 µM. It exhibits potent antiviral activity while demonstrating low cytotoxicity against WI-38 cells (IC50: 53.81 µM). SARS-CoV-2-IN-112 is applicable for coronavirus COVID-19 research.
Target:
SARS-CoV
* VAT and and shipping costs not included. Errors and price changes excepted